ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that Mark B. Knudson, Ph.D., Chief Executive Officer, is scheduled to present at the Canaccord Adams annual Diabetes and Obesity conference in New York on Tuesday, May 12 at 1:20 pm ET. Dr. Knudson will provide an overview of the Company and an update on its VBLOC® vagal blocking therapy development program.
